New agents in acute myeloid leukemia and other myeloid disorders
Open Access
- 20 January 2004
- Vol. 100 (3), 441-454
- https://doi.org/10.1002/cncr.11935
Abstract
Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all‐trans‐retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized. Cancer 2004. © 2003 American Cancer Society.Keywords
This publication has 99 references indexed in Scilit:
- Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingBlood, 2003
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003
- Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationBlood, 2003
- Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Role of FLT3 in leukemiaCurrent Opinion in Hematology, 2002
- Destabilizing Influences in ApoptosisCell, 2002
- Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidineBritish Journal of Haematology, 2001
- Multidrug resistance in haematological malignanciesJournal of Internal Medicine, 2000
- PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in VivoJournal of Biological Chemistry, 1995
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994